T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease

被引:121
作者
Bergmann, Christoph [1 ,4 ]
Strauss, Laura [1 ]
Wang, Yun [2 ]
Szczepanski, Miroslaw J. [1 ]
Lang, Stephan [4 ]
Johnson, Jonas T. [3 ]
Whiteside, Theresa L. [1 ,3 ]
机构
[1] Univ Pittsburgh, Inst Canc, Res Pavil Hillman Canc Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Inst Canc, Dept Biostat, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA
[4] Univ Duisburg Essen, Dept Otorhinolaryngol, Essen, Germany
关键词
D O I
10.1158/1078-0432.CCR-07-5126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Regulatory T cells play a major role in tumor escape from immunosurveillance. T regulatory cells type 1 (Tr1), a subset of regulatory T cells present in the tumor and peripheral circulation of patients with head and neck squamous cell carcinoma (HNSCC), mediate immune suppression and might contribute to tumor progression. Experimental Design: CD4(+)CD25(-)T cells were isolated from peripheral blood mononuclear cells (PBMC) or tumor-infiltrating lymphocytes (TIL) of 26 HNSCC patients and 10 normal controls. The Tr1 cell phenotype was determined before and after culture in the presence of interleukin (IL)-2, IL-10, and IL-15, each at 10 to 20 IU/mL. Suppression was measured in carboxyfluorescein diacetate succinimidyl ester - based proliferation assays with or without neutralizing anti-IL-10 or anti-transforming growth factor-beta(1) (TGF-beta(1)) monoclonal antibodies in Transwell systems. ELISA was used to define the Tr1 cytokine profile. Results: TO cells originate from CD4(+)CD25(-) precursors present in TIL and PBMC of HNSCC patients. Cytokine-driven ex vivo expansion of TO precursors yielded CD4(+)CD25(-)Foxp3(low)CD 132(+)IL-10(+)TGF-beta(+)(1) populations that mediated higher suppression than TO cells of normal controls (P < 0.0001). Tr1 cells suppressed proliferation of autologous responders via IL-10 and TGF-beta(1) secretion. Expression of these cytokines was higher in TIL-derived than PBMC-derived TO cells (P < 0.0001). The Tr1 cell frequency and suppressor function were significantly higher in patients presenting with advanced than early disease stages and in patients "cured" by oncologic therapies than in those with active disease. Conclusions: In HNSCC, Tr1 cell generation is promoted at the tumor site. Tr1 cells use TGF-beta and IL-10 to mediate suppression. They expand during disease progression and also following cancer therapy in patients with no evident disease.
引用
收藏
页码:3706 / 3715
页数:10
相关论文
共 43 条
[1]   Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones [J].
Adler, Adam J. .
CURRENT CANCER DRUG TARGETS, 2007, 7 (01) :3-14
[2]   Immune responses to p53 in patients with cancer:enrichment in tetramer+p53 peptide-specific T cells and regulatory T cells at tumor sites [J].
Albers, AE ;
Ferris, RL ;
Kim, GG ;
Chikamatsu, K ;
DeLeo, AB ;
Whiteside, TL .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) :1072-1081
[3]   Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers [J].
Badoual, C ;
Hans, S ;
Rodriguez, J ;
Peyrard, S ;
Klein, C ;
Agueznay, NE ;
Mosseri, V ;
Laccourreye, O ;
Bruneval, P ;
Fridman, WH ;
Brasnu, DF ;
Tartour, E .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :465-472
[4]   Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients [J].
Banerjee, Devi K. ;
Dhodapkar, Madhav V. ;
Matayeva, Elyana ;
Steinman, Ralph M. ;
Dhodapkar, Kavita M. .
BLOOD, 2006, 108 (08) :2655-2661
[5]   Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment [J].
Bergmann, Christoph ;
Strauss, Laura ;
Zeidler, Reinhard ;
Lang, Stephan ;
Whiteside, Theresa L. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (09) :1429-1442
[6]   Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma [J].
Bergmann, Christoph ;
Strauss, Laura ;
Zeidler, Reinhard ;
Lang, Stephan ;
Whiteside, Theresa L. .
CANCER RESEARCH, 2007, 67 (18) :8865-8873
[7]   Regulatory T cells in cancer [J].
Beyer, Marc ;
Schultze, Joachim L. .
BLOOD, 2006, 108 (03) :804-811
[8]   Head and neck cancer: past, present and future [J].
Chin, David ;
Boyle, Glen M. ;
Porceddu, Sandro ;
Theile, David R. ;
Parsons, Peter G. ;
Coman, William B. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (07) :1111-1118
[9]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[10]   Tregs and rethinking cancer immunotherapy [J].
Curiel, Tyler J. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) :1167-1174